FDA Approves Nasal Spray Influenza Vaccine for Self-Administration
New Delhi: The U.S. Food and Drug Administration (FDA) has granted approval for FluMist, a nasal spray influenza vaccine, to be administered by individuals themselves or by a caregiver. This groundbreaking move allows people aged 2 to 49 years to receive the flu vaccine without needing to visit a healthcare professional, thereby improving accessibility and convenience.
Read: Cabinet Approves ₹9,197 Crore Bio-RIDE Scheme to Boost Biotechnology Innovation
FluMist is designed to protect against the four most common strains of the influenza virus, including both subtypes A and B. Dr. Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research, highlighted the significance of this development, stating, “This approval enables a more flexible approach to flu prevention, which is especially crucial as we strive to increase vaccination coverage.”
The nasal spray formulation offers an alternative to traditional injections, making it particularly beneficial for those who have a fear of needles or limited access to medical facilities. The approval comes at a critical time, with health authorities emphasizing the importance of flu vaccination in reducing the strain on healthcare systems already burdened by COVID-19 and other seasonal illnesses.
Healthcare experts believe that this self-administration option could significantly boost vaccination rates, especially in remote and underserved areas. It also provides families with a more comfortable and less invasive method to protect against the flu.
News Source: https://www.fda.gov/news-events/press-announcements/fda-approves-nasal-spray-influenza-vaccine-self-or-caregiver-administration
